

**RAW SEQUENCE LISTING  
ERROR REPORT**



TECH CENTER 1600/2300

RECEIVED

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/579,543  
Source: 1629  
Date Processed by STIC: 1/17/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER  
VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND  
TRADEMARK OFFICE WEBSITE: SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom, including:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)

2. U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202

3. Hand Carry directly to:

U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name,  
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202

Or

U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,  
2011 South Clark Place, Arlington, VA 22202

4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,  
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202



RAW SEQUENCE LISTING  
PATENT APPLICATION NO. US 09/579,548

Input Seq: Amnseq1.txt  
Output Seq: NINCRF01172002-1579548.raw

Does Not Comply  
Corrected Diskette Needed

4 <110> APPLICANT: LAZARUS, Alan H.  
5 CROW, Andrew P.  
6 FREEDMAN, John  
8 <120> TITLE OF INVENTION: Method for isolating in vivo immune response  
10 <130> FILE REFERENCE: 711826-50751  
12 <140> CURRENT APPLICATION NUMBER: US/09/579,548  
12 <141> CURRENT FILING DATE: 2000-05-26  
12 <150> PRIOR APPLICATION NUMBER: 09/579,548  
14 <151> PRIOR FILING DATE: 2000-05-26  
15 <150> PRIOR APPLICATION NUMBER: CA 2,223,025  
16 <151> PRIOR FILING DATE: 1997-11-28  
18 <160> NUMBER OF SEQ ID NOS: 1  
20 <170> SOFTWARE: FastSEQ for Windows Version 3.0  
22 <210> SEQ ID NO: 1  
23 <211> LENGTH: 261  
24 <212> TYPE: PRT  
25 <213> ORGANISM: unknown  
W--> 27 <220> FEATURE:  
W--> 27 <223> OTHER INFORMATION:  
27 <400> SEQUENCE: 1  
28 Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly  
29 1 5 10 15  
30 Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu  
31 20 25 30  
32 Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg  
33 35 40 45  
34 Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val  
35 50 55 60  
36 Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser  
37 65 70 75 80  
38 Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys  
39 85 90 95  
40 Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asp Ser Phe Glu  
41 100 105 110  
42 Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser  
43 115 120 125  
44 Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly  
45 130 135 140  
46 Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln  
47 145 150 155 160  
48 Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr  
49 165 170 175  
50 Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser

delete - these are shown  
above in 21407 and  
21417

see item 11 on Env Summary Sheet

1. *Chlorophyll a* and *Chlorophyll b* were determined by the method of Arar and Collins (1971) using a Shimadzu 1601 UV-Visible Spectrophotometer.

100

1154

ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED

[illegible]

[illegible]

1/17/02

# Raw Sequence Listing Error Summary

## ERROR DETECTED

## SUGGESTED CORRECTION

## SERIAL NUMBER

529,543

ATTN: NEW RULES CASES PLEASE DISREGARD ENGLISH LANGUAGE HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1      Wrapped Nucleos  
    Wrapped Aminoac  
The number listed at the end of each line ("wrapped") should be the end line. This may occur if your file was reviewed in a word processor often creating it. Please adjust your right margins so that this will prevent "wrapping."
- 2      Invalid Line Length  
The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3      Misaligned Amino  
    Numbering  
The numbering under each 5' amino acids is misaligned. Do not use tab codes between numbers, use space characters, instead.
- 4      Non-ASCII  
The submitted file was not saved in ASCII (DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5      Variable Length  
Sequence(s)      contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6      Potential 2.0  
    "bug"  
A "bug" in Potential version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s)     . Normally, Potential would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7      Skipped Sequences  
    (OLD RULES)  
Sequence(s)      missing. If intentional, please insert the following lines for each skipped sequence:  
(1) INFORMATION FOR SEQ ID NO-X: (insert SEQ ID NO where "X" is shown)  
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  
(ii) SEQUENCE DESCRIPTION: SEQ ID NO-X: (insert SEQ ID NO where "X" is shown)  
This sequence is intentionally skipped  
  
Please also copy in "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8      Skipped Sequences  
    (NEW RULES)  
Sequence(s)      missing. If intentional, please insert the following lines for each skipped sequence.  
<210> sequence id number  
<210> sequence id number  
600
- 9      Use of n's or Xaa's  
    (NEW RULES)  
Use of n's or Xaa's have been detected in the Sequence Listing.  
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10      Invalid <213>  
    Responses  
Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence.
- 11      Use of <220>  
[Redacted area]
- 12      Potential 2.0  
    "bug"  
Please do not use "Copy to Disk" function of Potential version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13      Misuse of n  
n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7.

Other: \_\_\_\_\_


**Applicant must provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☐ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123  
For CRF submission help, call (703) 308-4212  
For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.



COPY OF PAPERS  
ORIGINALLY FILED



Practitioner's Docket No. 701826-050750

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re application of: Lazarus et al.

Application No.: 09/579,548

Group No.: 1644

Filed: May 26, 2000

Examiner: P. Gambel

For: METHOD FOR INHIBITING IN VIVO IMMUNE RESPONSE

APR 25 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>4/12/2002</u> Date	<u>Nicole M. Gignac</u> (type or print name of person mailing paper)
	<u></u> Signature of person mailing paper

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,  
AND/OR AMENDMENT PERTAINING THERETO  
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE  
AND/OR AMINO ACID SEQUENCE

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, David S. Resnick / Lana A. Shvartsman, state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith is/are:

A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e) and 1.824.

A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).

Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter.

In re application of: Lazarus et al.

Application No.: 09/579,548

Filed: May 26, 2000

For: METHOD FOR INHIBITING IN VIVO IMMUNE RESPONSE

Group No.: 1644

Examiner: P. Gambel

**STATEMENT THAT "SEQUENCE LISTING"  
AND COMPUTER READABLE COPY ARE THE SAME  
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

The "Sequence Listing" and computer readable copy are the same.


5. Fees

If any additional extension and/or fee is required, charge Account No. 50-0850.

Date: April 12, 2002

Respectfully submitted,

Customer No.: 26770

  
David S. Resnick (Reg. No. 34,235)  
Lana A. Shvartsman (Reg. No. 48,502)  
NIXON PEABODY LLP  
101 Federal Street  
Boston, MA 02110  
Tel. (617) 345-6057  
Fax (617) 345-1300